Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Michael P Randall, Andreas Rauschecker, Liam Gima-Lange, Jenai Wilmoth, Lingjing Chen, Ming Lu, Huimin Geng, Haifaa Abdulhaq, James L. Rubenstein

Blood (2023) 142 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2023-190698

Published: 2023

Journal Articles

Regulation of CNS Lymphoma Progression By the Myeloid Microenvironment

Hua-Xin Gao, Eleanor Fraser, Mario Merlini, Huimin Geng, Lingjing Chen, Ming Lu, Yasmin Moshfegh, Joseph Cleveland, Jae Ryu, Jigyasa Sharma, David A. Solomon, Katerina Akassoglou, Clifford Lowell, James L. Rubenstein

Blood (2021) 138 (Supplement 1): 448.

https://doi.org/10.1182/blood-2021-153839

Published: 2021

Journal Articles

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Elias J. Jabbour, Hagop Kantarjian, Ghayas C. Issa, Joseph Thaddeus Beck, Rebecca B. Klisovic, Sudipto Mukherjee, Vivian G. Oehler, Zi Chen, Ming Lu, Tommy Fu, Lixin Jiang, Yifan Zhai, Dajun Yang

Blood (2021) 138 (Supplement 1): 2551.

https://doi.org/10.1182/blood-2021-152693

Published: 2021

Journal Articles

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

Mingyuan Sun, Junyuan Qi, Zi Chen, Hongli Zhang, Yongping Song, Aizong Shen, Huilan Liu, Jianying Huang, Fuling Zhou, Jie Jin, Ming Lu, Mohammad Ahmad, Lichuang Men, Wan Cen, Dajun Yang, Jianxiang Wang, Yifan Zhai

Blood (2021) 138 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2021-152235

Published: 2021

Journal Articles

Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Ming Lu, PhD, Chenhui Deng, PhD, Yifeng Xiong, PhD, Hengbang Wang, Ping Xu, PhD, Lichuang Men, Tanhong Xie, Qian Jiang, MD, Zi Chen, MD, Qian Niu, MD, Ping Liu, PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141268

Published: 2020

Journal Articles

Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy

Naveen Pemmaraju, MD, Boyd Mudenda, MD MSc, MBBChir, Cunlin Wang, MD, Jiao JI, PhD MD, Ming Lu, PhD, Tommy Fu, PhD, Eric Liang, PhD, Sasha McClain, PharmD, Piyush Sheladia, MS, Srdan Verstovsek, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137260

Published: 2020

Journal Articles

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-142142

Published: 2020

Journal Articles

Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma

Huimin Geng, PhD, Brice Tiret, PhD, Hua-Xin Gao, PhD, Cigall Kadoch, PhD, Ming Lu, PhD, Lingjing Chen, PhD, Ilwoo Park, PhD, Gerd Melkus, PhD, Adam Elkhaled, PhD, John Kurhanewicz, PhD, Lisa Drew, PhD, Sebastien Degorce, PhD, Michele Mayo, PhD, Keith Dillman, PhD, Rana Anjum, PhD, Andrew Bloecher, PhD, Myriam Chaumeil, PhD, James Rubenstein, MD, PhD

Blood (2018) 132 (Supplement 1): 2840.

https://doi.org/10.1182/blood-2018-99-117625

Published: 2018

Journal Articles

Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma

Huimin Geng, PhD, Huaxin Gao, PhD, Cigall Kadoch, PhD, Ming Lu, Lingjing Chen, PhD, Rana Anjum, PhD, Lisa Drew, PhD, Sebastien Degorce, PhD, Keith Dillman, Michele Mayo, Shawn Anderson, Colin Collins, PhD, Clifford A. Lowell, MD PhD, James L. Rubenstein, MD, PhD

Blood (2016) 128 (22): 777.

https://doi.org/10.1182/blood.V128.22.777.777

Published: 2016

Journal Articles

Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia

Huimin Geng, PhD, Zhengshan Chen, PhD, Shawn Anderson, Eleanor Fraser, PhD, Ming Lu, Chen Lingjing, PhD, Colin Collins, PhD, Muschen Markus, PhD, James L. Rubenstein, MD PhD

Blood (2015) 126 (23): 3900.

https://doi.org/10.1182/blood.V126.23.3900.3900

Published: 2015

Journal Articles

The Role of FcγRIIa and TGF-β1/KLF6 Pathway in Platelet's Promoting Hepatocellular Carcinoma Cells Growth

Ao-Di He, Ming-Lu Liang, Gang Liu, Xing-Wen Da, Guang-Qiang Yao, Wen Xie, Ji-Zhou Xiang, Cunji Gao, MD PhD, Zhang-Yin Ming, MD PhD

Blood (2014) 124 (21): 1429.

https://doi.org/10.1182/blood.V124.21.1429.1429

Published: 2014

Journal Articles

Influence of Hemoglobin Level on Clinical Findings In Infants with Sickle Cell Anemia: Data From BABY HUG

Jeffrey D. Lebensburger, DO, Scott T Miller, MD, Thomas H. Howard, MD, James F. Casella, MD, R. Clark Brown, MD, PhD, Ming Lu, MS, Rathi V. Iyer, MD, Zora R. Rogers, MD, Winfred C. Wang, MD

Blood (2010) 116 (21): 1631.

https://doi.org/10.1182/blood.V116.21.1631.1631

Published: 2010

NARROW

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Regulation of CNS Lymphoma Progression By the Myeloid Microenvironment

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs)

Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy

Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma

Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma

Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia

The Role of FcγRIIa and TGF-β1/KLF6 Pathway in Platelet's Promoting Hepatocellular Carcinoma Cells Growth

Influence of Hemoglobin Level on Clinical Findings In Infants with Sickle Cell Anemia: Data From BABY HUG

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only